NAMS

21.98

5.07% 1.06

Handel nachbörslich: 21.98

Newamsterdam Pharma Company Nv (NAMS)

Überblick Nachrichten Preisverlauf Financials Warum fällt NAMS? Forum Prognose

Schlusskurs vom Vortag:

$20.92

Offen:

$20.69

24-Stunden-Volumen:

599.93K

Relative Volume:

0.77

Marktkapitalisierung:

$2.47B

Einnahmen:

$14.09M

Nettoeinkommen (Verlust:

$-176.94M

KGV:

-10.22

EPS:

-2.15

Netto-Cashflow:

$-141.24M

1W Leistung:

-0.18%

1M Leistung:

+18.88%

6M Leistung:

-6.67%

1J Leistung:

+16.85%

1-Tages-Spanne:

$20.53

$22.10

1-Wochen-Bereich:

$20.53

$22.75

52-Wochen-Spanne:

$14.06

$27.29

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Firmenname

Newamsterdam Pharma Company Nv

Sektor

Healthcare (1170)

Branche

Biotechnology (657)

Telefon

35 206 2971

Adresse

GOOIMEER 2-35, NARRDEN

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NAMS's Discussions on Twitter

Vergleichen Sie NAMS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NAMS Newamsterdam Pharma Company Nv	21.98	2.47B	14.09M	-176.94M	-141.24M	-2.15
VRTX Vertex Pharmaceuticals Inc	463.27	123.14B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	550.00	60.43B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	324.69	42.07B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	572.71	34.47B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	290.35	27.42B	3.81B	-644.79M	-669.77M	-6.24

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-17	Eingeleitet	Citigroup	Buy
2025-06-10	Eingeleitet	Stifel	Buy
2025-06-04	Eingeleitet	Cantor Fitzgerald	Overweight
2024-12-30	Eingeleitet	H.C. Wainwright	Buy
2024-05-15	Eingeleitet	TD Cowen	Buy
2024-03-14	Eingeleitet	Scotiabank	Sector Outperform
2024-01-18	Eingeleitet	Guggenheim	Buy
2024-01-16	Eingeleitet	Piper Sandler	Overweight
2023-10-30	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten

08:14 AM

Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target - MarketScreener

08:14 AM

07:42 AM

Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating By Investing.com - Investing.com Nigeria

07:42 AM

07:32 AM

Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating - Investing.com

07:32 AM

01:58 AM

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $42.89 Consensus Price Target from Analysts - Defense World

01:58 AM

Jul 16, 2025

Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) - MSN

Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025

Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionWatchlist Winner Update - Newser

Jul 16, 2025

Jul 15, 2025

Why NewAmsterdam Pharma Company N.V. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser

Jul 15, 2025

What makes NewAmsterdam Pharma Company N.V. stock price move sharplyFree Stock Market Insider Analysis - Newser

Jul 15, 2025

How NewAmsterdam Pharma Company N.V. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser

Jul 15, 2025

What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyAlpha Stock Ideas - Newser

Jul 15, 2025

Jul 11, 2025

NewAmsterdam Pharma updates employment agreement with chief scientific officer By Investing.com - Investing.com India

Jul 11, 2025

NewAmsterdam Pharma updates employment agreement with chief scientific officer - Investing.com

Jul 11, 2025

Jul 07, 2025

Mirae Asset Global Investments Co. Ltd. Purchases 596 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Defense World

Jul 07, 2025

Jul 05, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street Zen - Defense World

Jul 05, 2025

Jun 27, 2025

Thursday’s Insider Moves: Big Buys at NewAmsterdam Pharma, CME Group By Investing.com - Investing.com Nigeria

Jun 27, 2025

Jun 26, 2025

NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 26, 2025

Jun 18, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World

Jun 18, 2025

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria

Jun 18, 2025

Jun 17, 2025

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug By Investing.com - Investing.com South Africa

Jun 17, 2025

Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus

Jun 17, 2025

Jun 15, 2025

How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com

Jun 15, 2025

Jun 14, 2025

Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria

Jun 14, 2025

NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com India

Jun 14, 2025

Jun 13, 2025

NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com

Jun 13, 2025

NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 13, 2025

NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus

Jun 13, 2025

Jun 12, 2025

Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India

Jun 12, 2025

NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria

Jun 12, 2025

Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com

Jun 12, 2025

California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Jun 12, 2025

Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025